Yoshio Ijiri

836 total citations
56 papers, 658 citations indexed

About

Yoshio Ijiri is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Yoshio Ijiri has authored 56 papers receiving a total of 658 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Molecular Biology, 11 papers in Oncology and 10 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Yoshio Ijiri's work include Drug Transport and Resistance Mechanisms (7 papers), Drug-Induced Hepatotoxicity and Protection (6 papers) and Inflammasome and immune disorders (5 papers). Yoshio Ijiri is often cited by papers focused on Drug Transport and Resistance Mechanisms (7 papers), Drug-Induced Hepatotoxicity and Protection (6 papers) and Inflammasome and immune disorders (5 papers). Yoshio Ijiri collaborates with scholars based in Japan, Canada and Somalia. Yoshio Ijiri's co-authors include Ryuji Kato, Kazuhiko Tanaka, Yoshihiko Hirotani, Tetsuya Hayashi, Kenji Ikeda, Jack Uetrecht, Michiaki Myotoku, Takashi Umeda, Minoru Yoshiyama and Machiko Nakagawa and has published in prestigious journals such as Circulation, Journal of the American College of Cardiology and Chemosphere.

In The Last Decade

Yoshio Ijiri

56 papers receiving 642 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yoshio Ijiri Japan 14 187 108 98 93 78 56 658
Alaa E. El‐Sisi Egypt 17 312 1.7× 114 1.1× 189 1.9× 92 1.0× 57 0.7× 58 958
Abdel‐Aziz H. Abdel‐Aziz Egypt 15 255 1.4× 91 0.8× 52 0.5× 75 0.8× 66 0.8× 23 709
Jinghui Zhai China 19 351 1.9× 120 1.1× 136 1.4× 157 1.7× 58 0.7× 45 915
Hebatallah Husseini Atteia Egypt 16 140 0.7× 62 0.6× 71 0.7× 93 1.0× 43 0.6× 44 721
El‐Sayed M. El‐Sayed Egypt 16 118 0.6× 68 0.6× 57 0.6× 154 1.7× 60 0.8× 29 694
Nejat Kheiripour Iran 17 193 1.0× 91 0.8× 112 1.1× 59 0.6× 64 0.8× 55 891
Xiaoyu Qu China 19 321 1.7× 125 1.2× 176 1.8× 155 1.7× 56 0.7× 39 884
Peng Wen-xing China 19 194 1.0× 106 1.0× 145 1.5× 69 0.7× 87 1.1× 53 847
Hoda A. El‐Bahrawy Egypt 16 202 1.1× 79 0.7× 122 1.2× 59 0.6× 63 0.8× 28 720
Ivonne María Olivares-Corichi Mexico 15 174 0.9× 42 0.4× 79 0.8× 74 0.8× 41 0.5× 56 778

Countries citing papers authored by Yoshio Ijiri

Since Specialization
Citations

This map shows the geographic impact of Yoshio Ijiri's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yoshio Ijiri with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yoshio Ijiri more than expected).

Fields of papers citing papers by Yoshio Ijiri

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yoshio Ijiri. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yoshio Ijiri. The network helps show where Yoshio Ijiri may publish in the future.

Co-authorship network of co-authors of Yoshio Ijiri

This figure shows the co-authorship network connecting the top 25 collaborators of Yoshio Ijiri. A scholar is included among the top collaborators of Yoshio Ijiri based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yoshio Ijiri. Yoshio Ijiri is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Tanaka, Saori, et al.. (2024). Reactive metabolite of trovafloxacin activates inflammasomes: Implications for trovafloxacin‐induced liver injury. Journal of Applied Toxicology. 44(6). 846–852. 2 indexed citations
2.
Yamada, Tomoyuki, et al.. (2023). Disproportionality analysis of acetaminophen-induced hepatic disorders with and without immune checkpoint inhibitors. International Journal of Clinical Pharmacy. 45(2). 442–450. 2 indexed citations
3.
4.
Kato, Ryuji, Yoshio Ijiri, Takehiro Yamaguchi, et al.. (2018). Factor Xa inhibition by rivaroxaban attenuates cardiac remodeling due to intermittent hypoxia. Journal of Pharmacological Sciences. 137(3). 274–282. 23 indexed citations
5.
Kato, Ryuji, et al.. (2017). RIVAROXABAN ATTENUATES CARDIAC REMODELING DUE TO INTERMITTENT HYPOXIA BY SUPPRESSING THE SYNERGISTIC EFFECTS OF PAR-1 AND PAR-2. Journal of the American College of Cardiology. 69(11). 2033–2033. 2 indexed citations
6.
Kato, Ryuji, et al.. (2016). FACTOR XA INHIBITION BY RIVAROXABAN ATTENUATES CARDIAC REMODELING DUE TO HYPOXIC STRESS VIA PAR-2/ERK/NF-κB SIGNALING PATHWAY. Journal of the American College of Cardiology. 67(13). 2238–2238. 1 indexed citations
7.
Kato, Ryuji, et al.. (2014). Human Hepatocarcinoma Functional Liver Cell-4 Cell Line Exhibits High Expression of Drug-Metabolizing Enzymes in Three-Dimensional Culture. Biological and Pharmaceutical Bulletin. 37(11). 1782–1787. 11 indexed citations
8.
Hirose, Jun, Kouichi Sano, Ryuji Kato, et al.. (2011). Application of electrolysis for detoxification of an antineoplastic in urine. Ecotoxicology and Environmental Safety. 78. 123–127. 11 indexed citations
9.
Yamada, Tomoyuki, Kaoru Suzuki, Yoshio Ijiri, et al.. (2010). Interference Between Eplerenone and Digoxin in Fluorescence Polarization Immunoassay, Microparticle Enzyme Immunoassay, and Affinity Column-Mediated Immunoassay. Therapeutic Drug Monitoring. 32(6). 774–777. 8 indexed citations
10.
Kato, Ryuji, et al.. (2009). Is cyclosporine A transport inhibited by pravastatin via multidrug resistant protein 2?. European Journal of Clinical Pharmacology. 66(2). 153–158. 13 indexed citations
11.
Kato, Ryuji, et al.. (2009). Does the sedative agent, JM-1232(−) cause QT prolongation with subsequent torsades de pointes?. Life Sciences. 85(21-22). 737–741. 1 indexed citations
12.
Hirotani, Yoshihiko, Kenji Ikeda, Ryuji Kato, et al.. (2008). Protective Effects of Lactoferrin against Intestinal Mucosal Damage Induced by Lipopolysaccharide in Human Intestinal Caco-2 Cells. YAKUGAKU ZASSHI. 128(9). 1363–1368. 68 indexed citations
13.
Hirose, Jun, Kouichi Sano, Yoshio Ijiri, et al.. (2008). Evaluation of an electrolysis apparatus for inactivating antineoplastics in clinical wastewater. Chemosphere. 72(4). 659–665. 14 indexed citations
14.
Kato, Ryuji, et al.. (2007). Capsaicin Improves Survival Rate in Mice with Lipopolysaccharide-Induced Endotoxin Shock. 28(4). 307–313. 2 indexed citations
15.
Kato, Ryuji, et al.. (2007). Effects of lipopolysaccharide on intestinal P-glycoprotein expression and activity. European Journal of Pharmacology. 565(1-3). 220–224. 23 indexed citations
16.
Ijiri, Yoshio, Toru Inoue, Fumio Fukuda, et al.. (2004). Dialyzability of the Antiepileptic Drug Zonisamide in Patients Undergoing Hemodialysis. Epilepsia. 45(8). 924–927. 16 indexed citations
17.
Ijiri, Yoshio, Tohru Ogihara, Kaoru Suzuki, et al.. (2004). Increased digitalis-like immunoreactive substances in neonatal plasma measured using fluorescence polarization immunoassay. Journal of Clinical Pharmacy and Therapeutics. 29(6). 565–571. 4 indexed citations
18.
Doi, Mitsunobu, et al.. (2003). Crystal Structure of 5'-Hydroxythalidomide In Vivo Metabolite of Thalidomide in Humans. Analytical Sciences X-ray Structure Analysis Online. 19. X51–X52. 2 indexed citations
19.
20.
Ijiri, Yoshio, et al.. (1994). Clinical Pharmacokinetics of Zanisamide and Drug Interaction with Other Anticonvulsants.. Japanese Journal of Hospital Pharmacy. 20(3). 207–212. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alaa E. El‐Sisi Breakdown of academic impact, for papers by Abdel‐Aziz H. Abdel‐Aziz Breakdown of academic impact, for papers by Jinghui Zhai Breakdown of academic impact, for papers by Hebatallah Husseini Atteia Breakdown of academic impact, for papers by El‐Sayed M. El‐Sayed Breakdown of academic impact, for papers by Nejat Kheiripour Breakdown of academic impact, for papers by Xiaoyu Qu Breakdown of academic impact, for papers by Peng Wen-xing Breakdown of academic impact, for papers by Hoda A. El‐Bahrawy Breakdown of academic impact, for papers by Ivonne María Olivares-Corichi
Rankless by CCL
2026